Amgen Stock Tanks 5% Amid Sector News and Macro Pressures
Amgen stock plummeted by around 5 percent on September 16, 2026, after closing lower on the Nasdaq. The company's shares were affected by sector news, specifically fresh clinical data in the cardiovascular space that weighed heavily on its performance.
The decline was partly due to Novartis' cardiovascular medicine failing in clinical trials, which had a ripple effect across the industry and hit Amgen particularly hard given its significant weighting in the Dow Jones index. The Dow itself fell 1.21% on that day, but Amgen's drop exceeded this benchmark.
Investors reassessed their exposure to cardiometabolic and cardiovascular drug pipelines following Novartis' setbacks, with Amgen taking a hit due to its relatively high weighting in the Dow Jones index. The overall market sentiment was risk-off, driven by expectations of tighter monetary policy after the Federal Reserve signaled a rate hike.
Looking ahead to September 17, 2026, investors will be watching both company-specific pipeline developments and broader macro dynamics. Amgen's resilience in past downturns and its dividend profile may shape how income-focused investors view recent volatility, especially considering the stock's history of outperforming the S&P 500 in stress episodes.